BioCentury | Feb 14, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: January 2019

...culture and mouse studies identified a bicyclic HSD17B2 inhibitor that could help treat bone fractures ElexoPharm GmbH...
BioCentury | Jan 23, 2019
Distillery Therapeutics

Musculoskeletal

...bone stiffness and callus volume at the fracture site compared with vehicle. Next steps by ElexoPharm GmbH...
...online Jan. 15, 2019 doi:10.1021/acs.jmedchem.8b01493 CONTACT: Chris J. van Koppen, ElexoPharm GmbH, Saarbrücken, Germany email: vankoppen@elexopharm.de Hongjiang Li ElexoPharm GmbH Hydroxysteroid...
BioCentury | Oct 22, 2012
Company News

ElexoPharm, SomantiX B.V., PharmBioTec GmbH, Saarland University, VU University Medical Center cancer news

...million) to a consortium to develop low molecular weight inhibitors of angiogenesis in colorectal cancer. ElexoPharm...
...of public funding agencies from Austria, Belgium, Finland, France, Germany, Hungary, Italy, Russia and Spain. ElexoPharm GmbH...
BioCentury | May 28, 2012
Company News

ElexoPharm, Khondrion B.V., Pharmacelsus GmbH, Radboud University Nijmegen Medical Centre pharmaceuticals news

...A consortium consisting of Khondrion, ElexoPharm, Pharmacelsus and Radboud received a three-year €2.1 million ($2.7 million...
...of Education and Research, under the Eurostars R&D program, to discover therapies for mitochondrial diseases. ElexoPharm...
...the university will conduct in vivo preclinical testing on selected compounds. Details were not disclosed. ElexoPharm GmbH...
BioCentury | Apr 23, 2012
Company News

ElexoPharm management update

ElexoPharm GmbH , Saarbruecken, Germany Business: Supply/Service, Chemistry Appointed: Chris van Koppen as head of research, a newly created position, formerly a research fellow at Merck & Co. Inc. WIR Staff...
BioCentury | May 24, 2010
Company News

ElexoPharm, Merck deal

...is responsible for all development, regulatory filings, manufacturing and commercialization of compounds under the deal. ElexoPharm...
...front and is eligible for up to €32.3 million ($39.9 million) in milestones, plus royalties. ElexoPharm GmbH...
Items per page:
1 - 6 of 6
BioCentury | Feb 14, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: January 2019

...culture and mouse studies identified a bicyclic HSD17B2 inhibitor that could help treat bone fractures ElexoPharm GmbH...
BioCentury | Jan 23, 2019
Distillery Therapeutics

Musculoskeletal

...bone stiffness and callus volume at the fracture site compared with vehicle. Next steps by ElexoPharm GmbH...
...online Jan. 15, 2019 doi:10.1021/acs.jmedchem.8b01493 CONTACT: Chris J. van Koppen, ElexoPharm GmbH, Saarbrücken, Germany email: vankoppen@elexopharm.de Hongjiang Li ElexoPharm GmbH Hydroxysteroid...
BioCentury | Oct 22, 2012
Company News

ElexoPharm, SomantiX B.V., PharmBioTec GmbH, Saarland University, VU University Medical Center cancer news

...million) to a consortium to develop low molecular weight inhibitors of angiogenesis in colorectal cancer. ElexoPharm...
...of public funding agencies from Austria, Belgium, Finland, France, Germany, Hungary, Italy, Russia and Spain. ElexoPharm GmbH...
BioCentury | May 28, 2012
Company News

ElexoPharm, Khondrion B.V., Pharmacelsus GmbH, Radboud University Nijmegen Medical Centre pharmaceuticals news

...A consortium consisting of Khondrion, ElexoPharm, Pharmacelsus and Radboud received a three-year €2.1 million ($2.7 million...
...of Education and Research, under the Eurostars R&D program, to discover therapies for mitochondrial diseases. ElexoPharm...
...the university will conduct in vivo preclinical testing on selected compounds. Details were not disclosed. ElexoPharm GmbH...
BioCentury | Apr 23, 2012
Company News

ElexoPharm management update

ElexoPharm GmbH , Saarbruecken, Germany Business: Supply/Service, Chemistry Appointed: Chris van Koppen as head of research, a newly created position, formerly a research fellow at Merck & Co. Inc. WIR Staff...
BioCentury | May 24, 2010
Company News

ElexoPharm, Merck deal

...is responsible for all development, regulatory filings, manufacturing and commercialization of compounds under the deal. ElexoPharm...
...front and is eligible for up to €32.3 million ($39.9 million) in milestones, plus royalties. ElexoPharm GmbH...
Items per page:
1 - 6 of 6